Milestone Pharmaceuticals
MIST
31 hedge funds and large institutions have $113M invested in Milestone Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 6 increasing their positions, 3 reducing their positions, and 6 closing their positions.
207% more capital invested
Capital invested by funds: $36.9M → $113M (+$76.5M)
117% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 6
100% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 3
29% more funds holding
Funds holding: 24 → 31 (+7)
23.06% more ownership
Funds ownership: 39.6% → 62.66% (+23%)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $523K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.3M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$12.5M |
| 3 |
BC
Boxer Capital
San Diego,
California
|
+$4.84M |
| 4 |
O
OrbiMed
New York
|
+$2.77M |
| 5 |
Millennium Management
New York
|
+$2.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$642K |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$455K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$125K |
| 4 |
SAMH
Shanda Asset Management Holdings
Tortola,,
British Virgin Islands
|
-$98K |
| 5 |
Two Sigma Advisers
New York
|
-$79K |
MIST Hedge Fund Activity: Q3 2020 in Review
31 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q3 2020, worth a combined $113M — up 207% from $36.9M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new MIST positions and 6 closed out — a net gain of 7 holders — while 6 added to existing stakes and 3 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $17.3M. The largest seller was K2 Principal Fund, exiting entirely with an estimated $642K sold.
- 31 institutional investors held Milestone Pharmaceuticals (MIST) as of Q3 2020, up from 24 in Q2 2020.
- Funds reported $113M of Milestone Pharmaceuticals stock for Q3 2020, up 207% quarter-over-quarter.
- 13 funds opened new Milestone Pharmaceuticals positions in Q3 2020 and 6 closed out, a net change of +7 holders.
- The largest Milestone Pharmaceuticals buyer in Q3 2020 was RA Capital Management, an estimated $17.3M added.
- The largest Milestone Pharmaceuticals seller in Q3 2020 was K2 Principal Fund, an estimated $642K sold.
Based on aggregated 13F filings for Q3 2020.